PharmaResearch Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Sang-Soo Jung
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 34.5% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
No updates
Recent updates
What PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 32% Share Price Gain Is Not Telling You
Dec 19
PharmaResearch Co., Ltd. (KOSDAQ:214450) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Aug 15Here's Why We Think PharmaResearch (KOSDAQ:214450) Might Deserve Your Attention Today
May 21PharmaResearch Co., Ltd.'s (KOSDAQ:214450) 33% Share Price Surge Not Quite Adding Up
Apr 09Is Pharma Research Products (KOSDAQ:214450) A Risky Investment?
Mar 23Are Investors Undervaluing Pharma Research Products Co., Ltd (KOSDAQ:214450) By 50%?
Mar 05Should You Be Adding Pharma Research Products (KOSDAQ:214450) To Your Watchlist Today?
Feb 17Introducing Pharma Research Products (KOSDAQ:214450), A Stock That Climbed 65% In The Last Year
Feb 02
Pharma Research Products Co., Ltd (KOSDAQ:214450) Is Yielding 0.5% - But Is It A Buy?
Jan 20Here's What Pharma Research Products Co., Ltd's (KOSDAQ:214450) Shareholder Ownership Structure Looks Like
Jan 07Declining Stock and Solid Fundamentals: Is The Market Wrong About Pharma Research Products Co., Ltd (KOSDAQ:214450)?
Dec 23Is Pharma Research Products (KOSDAQ:214450) Using Too Much Debt?
Dec 08Is Pharma Research Products Co., Ltd (KOSDAQ:214450) Trading At A 43% Discount?
Nov 25CEO
Sang-Soo Jung (66 yo)
no data
Tenure
Mr. Sang-Soo Jung serves as the Chief Executive Officer of PharmaReaserch Products Co., Ltd. and PharmaResearch Co., Ltd. (formerly known as Pharma Research Products Co., Ltd).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 12:24 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PharmaResearch Co., Ltd. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sae-rom Lee | Daishin Securities Co. Ltd. |
| Jonghyun Park | DAOL Investment & Securities Co., Ltd. |
| Tae-Na Jo | Eugene Investment & Securities Co Ltd. |